Related Experiment Video

Updated: Aug 25, 2026

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.9K

Severe neutropenia after rituximab-treatment of multiple sclerosis

Eero Rissanen1, Kari Remes2, Laura Airas1

  • 1Division of Clinical Neurosciences, Turku University Hospital and University of Turku, Turku, Finland.

Multiple Sclerosis and Related Disorders
|December 19, 2017
PubMed

Insights

Rituximab treatment for multiple sclerosis (MS) can cause severe neutropenia, a dangerous drop in white blood cells. Prompt treatment with granulocyte-colony stimulating factor (G-CSF) resolved the issue, highlighting the need for careful patient monitoring.

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Rituximab is an effective B-cell depleting therapy used in MS treatment.
  • Neutropenia is a known potential side effect of rituximab therapy.

Observation:

  • This report details the first documented case of grade IV neutropenia in an MS patient receiving rituximab.
  • The patient required hospitalization and treatment for a serious infection due to severe neutropenia.
  • Neutropenia resolved promptly following treatment with granulocyte-colony stimulating factor (G-CSF).

Findings:

  • Rituximab treatment can lead to profound and potentially life-threatening neutropenia in MS patients.
  • Early recognition and intervention with G-CSF are crucial for managing rituximab-induced neutropenia.
  • Due to the risk of recurrence, rituximab was discontinued in this patient.

Implications:

  • Clinicians must be vigilant in monitoring MS patients for neutropenia during rituximab therapy.
  • Understanding the mechanisms of rituximab-induced neutropenia is essential for risk mitigation.
  • This case underscores the importance of risk-benefit assessment in MS treatment strategies.
Keywords:
GranulocytopeniaMultiple sclerosisNeutropeniaRituximab

More Related Videos

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.9K
Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay05:52

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay

Published on: May 12, 2023

1.9K

Related Concept Videos

Rocky Mountain Spotted Fever01:26

Rocky Mountain Spotted Fever

Rocky Mountain Spotted Fever (RMSF) is a severe tick-borne illness caused by Rickettsia rickettsii, a Gram-negative, coccobacillary bacterium. This pathogen is an obligate intracellular parasite, requiring a host cell for replication. Transmission occurs through the bite of an infected tick. In the United States, the most important vectors are Dermacentor variabilis (American dog tick) and Dermacentor andersoni (Rocky Mountain wood tick), though other tick species may also serve as vectors.
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...